A Phase 2 interventional study of Selinexor in Ovarian Carcinoma, Endometrial Carcinoma and Cervical Carcinoma, sponsored by Karyopharm Therapeutics Inc. Completed at 4 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Ovarian Neoplasms with a site in Denmark — 17 open to participants now, 27 under way, 15 of them phase 3. Ovarian Neoplasms · Denmark.
Among the 104 studies in Ovarian Neoplasms with a site in Denmark, this one is the 56th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2014, is one of 21 in phase 2, and was the 39th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →17 of the 104 studies in Ovarian Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 70+ · Women only
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Denmark, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in Denmark, United States, Australia and 13 more countries
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in Denmark, United States, Argentina and 27 more countries
Ages 18+ · Women only
AbbVie · Sites in Denmark, United States, Australia and 5 more countries
Ages 18+ · Women only
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 34 · Phase 3 41
First in 1995; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 237 across the 90 interventional studies, 223 across the 13 observational. Of the 69 that completed or were terminated, 23 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 104 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Ovarian Neoplasms with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 104 studies in Ovarian Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Two-stage Phase 2 study in 3 separate gynecological cancer cohorts, with an additional set of participants in the ovarian cohort randomized into 2 different treatment regimens. The study is divided between a Primary Treatment Phase and a Maintenance Phase with each phase supported by a separate database.
Part 1 - Three parallel cohorts of participants with ovarian (Cohort A), endometrial (Cohort B), or cervical (Cohort C) carcinoma were enrolled.
Part 2 - Based on the observed tolerability and efficacy profile in the ongoing ovarian cohort (Cohort A), 2 additional treatment schedules will be explored to optimize the dosing schedule in a participant population with ovarian carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematologic function defined as:
Ovarian, fallopian tube, or peritoneal carcinoma: both platinum * and platinum resistant** participants, who have received ≥1 for relapsed disease (i.e., ≥2 lines of chemotherapy in total).
*Platinum refractory is defined as progression during or within 4 weeks of last treatment with a platinum-containing therapy.
**Platinum resistant is defined as relapse 4 weeks to \<6 months after a platinum-containing therapy.
Exclusion Criteria:
Disease-Specific Exclusions:
Unstable cardiovascular function:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m\^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
Drug: Selinexor
Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
Drug: Selinexor
Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
Drug: Selinexor
Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
Drug: Selinexor
Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m\^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
Drug: Selinexor
Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW. Treatment cycles were 4 weeks each i.e., 28 day cycles.
Also known as: KPT-330, XPOVIO
Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Disease Control Rate (DCR) was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) for at least 12 weeks, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants without documented disease progression were censored on the date of last radiologic assessment.
Time frame: Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)
Percentage of Participants With Overall Response According to RECIST v1.1
Overall Response Rate (ORR) was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline up to the date of progression or recurrence (approximately 35 months)
Percentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria
DCR was defined as the point estimate of the percentage of participants who had CR, PR, or SD for at least 12 weeks, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).
Time frame: Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)
Percentage of Participants With Overall Response According to GCIG Response Criteria
ORR was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).
Time frame: Baseline up to the date of progression or recurrence (approximately 35 months)
Progression-free Survival (PFS) According to RECIST v1.1
PFS was defined as the time from date of start of study therapy to the date of tumor disease progression (i.e., radiological only) or date of death due to any cause. Participants without documented disease progression were censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.
Time frame: From start of study drug administration until PD or discontinuation from the study or death, whichever occurred first (approximately 35 months)
Overall Survival (OS)
OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or were lost to follow-up were censored at the day they were last known to be alive. Kaplan-Maier method was used for estimation.
Time frame: From start of study treatment up to the date of death, assessed every 3 months (approximately 35 months)
Percentage of Participants Who Survived at 12 and 24 Months
OS rate was reported as the percentage of participants who were alive at 12 and 24 months. OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or are lost to follow-up were censored at the day they were last known to be alive. Survival rate were estimated by Kaplan-Maier method.
Time frame: 12 and 24 months
Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAE) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not it is considered related to the medicinal product. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria, i.e., fatal, life threatening (places the participants at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. TEAE was defined as any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.
Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
Number of Participants With Treatment-emergent Adverse Events by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE, Version 4.03
AE: any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal product, whether or not it is considered related to medicinal product. TEAE: any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study drug through 30 days following last dose or any event considered drug-related by investigator through end of study. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.
Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
Quality of Life (QoL): Change From Baseline European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQC30) Scores
EORTC QLQC30: Disease specific indication that rates overall QoL in cancer participants. It consists of 30 general questions from 3 domains; 1) global health status, 2) functioning scales (physical, emotional, cognitive, social and role functioning), 3) symptom scales (fatigue, nausea, vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulty). Out of 30 questions, 28 questions were scored using scale of 1 to 4, represented answers of 'not at all', 'a little', 'quite a bit', and 'very much'; remaining 2 questions contributed to global health status were scored on scale of 1 to 7, represented range of 'very poor' to 'excellent' that evaluated overall health and QoL. All scales and single-item measures range from 0 to 100, where higher score represented higher response level. Higher score for functional scale, global health status and symptom scale represented high level of functioning, high QoL, and high level of symptoms or problems, respectively.
Time frame: Baseline, End of treatment (EOT) i.e., 30 days after last dose of study drug administration (up to 31 months)
Number of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests
Clinically significant laboratory tests abnormalities were analyzed and reported for this outcome measure.
Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
The study was conducted between 09-April-2014 and 29-Mar-2017.
| Milestone | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWmg/m^2 | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Started | 25 | 23 | 25 | 21 | 20 |
| Modified intent-to-treat(mitt)population | 23 | 22 | 25 | 21 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 25 | 23 | 25 | 21 | 20 |
| Withdrew: Consent withdrawn | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Termination of study by sponsor | 4 | 3 | 1 | 1 | 3 |
| Withdrew: Death | 21 | 20 | 23 | 20 | 17 |
Disease Control Rate (DCR) was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) for at least 12 weeks, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants without documented disease progression were censored on the date of last radiologic assessment.
| percentage of participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 30.4 (13.2 to 52.9) | 36.4 (17.2 to 59.3) | 24.0 (9.4 to 45.1) | 33.3 (14.6 to 57.0) | 30.0 (11.9 to 54.3) |
Overall Response Rate (ORR) was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Percentage of Participants With Overall Response According to RECIST v1.1 | 8.7 (1.1 to 28.0) | 13.6 (2.9 to 34.9) | 4.0 (0.1 to 20.4) | 9.5 (1.2 to 30.4) | 15.0 (3.2 to 37.9) |
DCR was defined as the point estimate of the percentage of participants who had CR, PR, or SD for at least 12 weeks, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).
| percentage of participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|
| Percentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria | 16.0 (4.5 to 36.1) | 23.8 (8.2 to 47.2) | 20.0 (5.7 to 43.7) |
ORR was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).
| percentage of participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|
| Percentage of Participants With Overall Response According to GCIG Response Criteria | 4.0 (0.1 to 20.4) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) |
PFS was defined as the time from date of start of study therapy to the date of tumor disease progression (i.e., radiological only) or date of death due to any cause. Participants without documented disease progression were censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.
| days | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) According to RECIST v1.1 | 79.0 (45.0 to 99.0) | 86.5 (43.0 to 182.0) | 44.0 (43.0 to 141.0) | 85.0 (44.0 to 148.0) | 44.5 (43.0 to 140.0) |
OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or were lost to follow-up were censored at the day they were last known to be alive. Kaplan-Maier method was used for estimation.
| days | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Overall Survival (OS) | 172.0 (62.0 to 372.0) | 226.0 (111.0 to 449.0) | 152.0 (83.0 to 254.0) | 348.0 (149.0 to 401.0) | 173.0 (105.0 to 353.0) |
OS rate was reported as the percentage of participants who were alive at 12 and 24 months. OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or are lost to follow-up were censored at the day they were last known to be alive. Survival rate were estimated by Kaplan-Maier method.
| percentage of participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| 12 months | 34.8 (16.6 to 53.7) | 31.8 (14.2 to 51.1) | 13.2 (3.4 to 29.9) | 33.3 (14.9 to 53.1) | 25.0 (9.1 to 44.9) |
| 24 months | 21.7 (7.9 to 39.9) | 13.6 (3.4 to 30.9) | 4.4 (0.3 to 18.4) | 19.0 (5.9 to 37.7) | 15.0 (3.7 to 33.5) |
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not it is considered related to the medicinal product. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria, i.e., fatal, life threatening (places the participants at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. TEAE was defined as any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.
| Participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Participants with TEAE | 25 | 23 | 25 | 21 | 20 |
| Participants with TESAE | 14 | 14 | 6 | 12 | 12 |
AE: any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal product, whether or not it is considered related to medicinal product. TEAE: any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study drug through 30 days following last dose or any event considered drug-related by investigator through end of study. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.
| Participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Mild (Grade 1) | 0 | 0 | 0 | 0 | 0 |
| Moderate (Grade 2) | 3 | 3 | 5 | 5 | 7 |
| Severe (Grade 3) | 19 | 17 | 17 | 15 | 13 |
| Life threatening (Grade 4) | 3 | 2 | 2 | 1 | 0 |
| Fatal (Grade 5) | 0 | 1 | 1 | 0 | 0 |
EORTC QLQC30: Disease specific indication that rates overall QoL in cancer participants. It consists of 30 general questions from 3 domains; 1) global health status, 2) functioning scales (physical, emotional, cognitive, social and role functioning), 3) symptom scales (fatigue, nausea, vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulty). Out of 30 questions, 28 questions were scored using scale of 1 to 4, represented answers of 'not at all', 'a little', 'quite a bit', and 'very much'; remaining 2 questions contributed to global health status were scored on scale of 1 to 7, represented range of 'very poor' to 'excellent' that evaluated overall health and QoL. All scales and single-item measures range from 0 to 100, where higher score represented higher response level. Higher score for functional scale, global health status and symptom scale represented high level of functioning, high QoL, and high level of symptoms or problems, respectively.
| scores on a scale | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Global Health Status/ QoL: Baseline | 52.8 ± 22.41 | 59.5 ± 20.63 | 60.2 ± 24.25 | 61.5 ± 22.89 | 57.5 ± 21.95 |
| Global Health Status/ QoL: EOT | -8.3 ± 11.79 | -11.4 ± 29.88 | -14.6 ± 10.49 | -27.4 ± 31.81 | -13.9 ± 15.52 |
| Functioning Scales/ Physical Functioning: Baseline | 69.5 ± 19.16 | 70.9 ± 21.54 | 66.1 ± 26.02 | 67.1 ± 21.14 | 70.7 ± 25.26 |
| Functioning Scales/ Physical Functioning: EOT | -26.7 ± 28.28 | -16.4 ± 27.55 | -24.2 ± 21.32 | -7.6 ± 16.97 | -18.9 ± 14.25 |
| Functioning Scales/ Role Functioning: Baseline | 54.0 ± 29.77 | 59.5 ± 31.87 | 55.6 ± 35.49 | 59.5 ± 28.66 | 63.3 ± 34.45 |
| Functioning Scales/ Role Functioning: EOT | -33.3 ± 47.14 | -3.0 ± 49.90 | -20.8 ± 36.96 | -9.5 ± 39.51 | -25.0 ± 9.13 |
| Functioning Scales/ Emotional Functioning: Baseline | 62.3 ± 24.81 | 69.8 ± 24.65 | 71.2 ± 23.81 | 74.2 ± 19.53 | 66.3 ± 23.33 |
| Functioning Scales/ Emotional Functioning: EOT | -16.7 ± 11.79 | -0.8 ± 38.27 | 12.5 ± 14.43 | -13.9 ± 23.07 | -2.8 ± 17.21 |
| Functioning Scales/ Cognitive Functioning: Baseline | 81.0 ± 22.54 | 86.5 ± 16.35 | 83.3 ± 25.20 | 83.3 ± 19.00 | 80.8 ± 23.12 |
| Functioning Scales/ Cognitive Functioning: EOT | -33.3 ± 23.57 | -6.1 ± 29.13 | 4.2 ± 20.97 | -16.7 ± 38.49 | 0.0 ± 0.00 |
| Functioning Scales/ Social Functioning: Baseline | 61.1 ± 29.97 | 76.2 ± 32.31 | 72.7 ± 28.89 | 69.0 ± 30.86 | 77.5 ± 29.75 |
| Functioning Scales/ Social Functioning: EOT | -33.3 ± 0.00 | -6.1 ± 48.46 | -20.8 ± 20.97 | -7.1 ± 18.90 | -30.6 ± 32.35 |
| Symptom Scales/Items/ Fatigue: Baseline | 46.6 ± 27.80 | 43.4 ± 27.42 | 44.9 ± 27.75 | 46.0 ± 27.28 | 41.7 ± 27.89 |
| Symptom Scales/Items/ Fatigue: EOT | 33.3 ± 47.14 | 6.1 ± 41.09 | 1.4 ± 17.20 | 23.8 ± 30.38 | 16.7 ± 11.65 |
| Symptom Scales/Items/ Nausea And Vomiting: Baseline | 13.5 ± 24.51 | 17.5 ± 30.04 | 9.8 ± 15.99 | 5.6 ± 14.27 | 10.8 ± 21.81 |
| Symptom Scales/Items/ Nausea And Vomiting: EOT | 8.3 ± 11.79 | -0.0 ± 40.82 | 16.7 ± 19.25 | 9.5 ± 23.29 | 13.9 ± 16.39 |
| Symptom Scales/Items/ Pain: Baseline | 34.9 ± 27.84 | 37.3 ± 27.34 | 32.6 ± 27.93 | 31.0 ± 29.48 | 32.5 ± 26.75 |
| Symptom Scales/Items/ Pain: EOT | -8.3 ± 11.79 | -4.5 ± 21.20 | 4.2 ± 8.33 | -2.4 ± 17.82 | 2.8 ± 26.70 |
| Symptom Scales/Items/ Dyspnoea: Baseline | 23.8 ± 31.87 | 30.2 ± 36.37 | 19.7 ± 30.27 | 33.3 ± 38.01 | 21.7 ± 29.17 |
| Symptom Scales/Items/ Dyspnoea: EOT | 50.0 ± 23.57 | 6.1 ± 32.72 | 8.3 ± 16.67 | -0.0 ± 47.14 | 16.7 ± 18.26 |
| Symptom Scales/Items/ Insomnia: Baseline | 31.7 ± 34.12 | 36.5 ± 31.46 | 30.3 ± 32.38 | 20.6 ± 26.82 | 38.3 ± 29.17 |
| Symptom Scales/Items/ Insomnia: EOT | -16.7 ± 23.57 | -9.1 ± 30.15 | -16.7 ± 33.33 | -19.0 ± 26.23 | 5.6 ± 32.77 |
| Symptom Scales/Items/ Appetite Loss: Baseline | 25.4 ± 31.46 | 34.9 ± 32.45 | 30.3 ± 36.96 | 23.8 ± 28.17 | 15.0 ± 27.52 |
| Symptom Scales/Items/ Appetite Loss: EOT | 16.7 ± 23.57 | 0.0 ± 53.75 | 16.7 ± 43.03 | 33.3 ± 47.14 | 16.7 ± 34.96 |
| Symptom Scales/Items/ Constipation: Baseline | 27.0 ± 27.12 | 15.9 ± 24.99 | 15.2 ± 26.68 | 17.5 ± 30.95 | 11.7 ± 16.31 |
| Symptom Scales/Items/ Constipation: EOT | 0.0 ± 47.14 | 6.7 ± 43.89 | 8.3 ± 16.67 | 9.5 ± 31.71 | -5.6 ± 13.61 |
| Symptom Scales/Items/ Diarrhoea: Baseline | 17.5 ± 30.95 | 9.5 ± 26.13 | 18.2 ± 24.62 | 18.3 ± 31.48 | 8.3 ± 14.81 |
| Symptom Scales/Items/ Diarrhoea: EOT | 0.0 ± 0.00 | -3.0 ± 34.82 | 0.0 ± 27.22 | 23.8 ± 25.20 | 27.8 ± 32.77 |
| Symptom Scales/Items/ Financial Difficulties: Baseline | 7.9 ± 17.97 | 4.8 ± 15.94 | 16.7 ± 26.73 | 9.5 ± 18.69 | 5.0 ± 12.21 |
| Symptom Scales/Items/ Financial Difficulties: EOT | 16.7 ± 23.57 | 3.0 ± 17.98 | 0.0 ± 0.00 | 4.8 ± 29.99 | -5.6 ± 13.61 |
Clinically significant laboratory tests abnormalities were analyzed and reported for this outcome measure.
| Participants | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| Number of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests | 21 | 20 | 19 | 14 | 11 |
Collected over From start of study treatment up to 30 days after last dose administration (approximately 35 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | 21/25 (84%) | 14/25 (56%) | 25/25 (100%) |
| Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | 20/23 (87%) | 14/23 (60.9%) | 23/23 (100%) |
| Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | 23/25 (92%) | 6/25 (24%) | 25/25 (100%) |
| Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | 20/21 (95.2%) | 12/21 (57.1%) | 21/21 (100%) |
| Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW | 17/20 (85%) | 12/20 (60%) | 20/20 (100%) |
| Event | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 5/25 | 1/23 | 0/25 | 0/21 | 0/20 |
| AscitesGastrointestinal disorders | 2/25 | 0/23 | 0/25 | 0/21 | 4/20 |
| NauseaGastrointestinal disorders | 0/25 | 1/23 | 1/25 | 0/21 | 2/20 |
| General Physical Health DeteriorationGeneral disorders | 0/25 | 0/23 | 0/25 | 0/21 | 2/20 |
| HyponatraemiaMetabolism and nutrition disorders | 0/25 | 2/23 | 0/25 | 0/21 | 0/20 |
| Deep Vein ThrombosisVascular disorders | 0/25 | 2/23 | 0/25 | 0/21 | 1/20 |
| IleusGastrointestinal disorders | 2/25 | 0/23 | 0/25 | 1/21 | 0/20 |
| DehydrationMetabolism and nutrition disorders | 2/25 | 1/23 | 0/25 | 1/21 | 0/20 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/25 | 1/23 | 0/25 | 0/21 | 0/20 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/25 | 0/23 | 0/25 | 0/21 | 1/20 |
| Event | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 22/25 | 15/23 | 17/25 | 17/21 | 15/20 |
| Decreased AppetiteMetabolism and nutrition disorders | 12/25 | 18/23 | 12/25 | 16/21 | 10/20 |
| VomitingGastrointestinal disorders | 18/25 | 14/23 | 11/25 | 13/21 | 12/20 |
| Weight DecreasedInvestigations | 12/25 | 13/23 | 18/25 | 11/21 | 6/20 |
| FatigueGeneral disorders | 12/25 | 15/23 | 15/25 | 14/21 | 14/20 |
| AnaemiaBlood and lymphatic system disorders | 13/25 | 11/23 | 14/25 | 9/21 | 5/20 |
| ConstipationGastrointestinal disorders | 7/25 | 6/23 | 6/25 | 11/21 | 7/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/25 | 10/23 | 13/25 | 4/21 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 6/25 | 7/23 | 6/25 | 10/21 | 8/20 |
| DysgeusiaNervous system disorders | 7/25 | 5/23 | 11/25 | 4/21 | 6/20 |
Baseline analysis was performed on safety population that included all participants who had received any amount of study drug.
| Age, Categorical(Participants) | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 6 | 20 | 13 | 14 | 70 |
| >=65 years | 8 | 17 | 5 | 8 | 6 | 44 |
| Sex: Female, Male(Participants) | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW | Total |
|---|---|---|---|---|---|---|
| Female | 25 | 23 | 25 | 21 | 20 | 114 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 25 | 23 | 25 | 21 | 20 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW | Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW | Total |
|---|---|---|---|---|---|---|
| Race — White | 25 | 23 | 24 | 21 | 20 | 113 |
| Race — Other-unspecified | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in Jan 2017, 33 months.
Results were first posted in Feb 2021, 4 years after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 33 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor